KPTI logo

Karyopharm Therapeutics (KPTI) EBITDA

Annual EBITDA

-$38.60 M
+$79.82 M+67.40%

December 31, 2024

Summary

Performance

1-Year Change

+67.4%

3-Year Change

+60.2%

5-Year Change

+78.9%

15-Year Change

+69.89%

KPTI EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

38.21%
KPTI annual EBITDA is higher than 38.21% of companies in Healthcare sector

High & Low

All-time High

-$10.23 M

3-Year Low

-$139.31 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
KPTI previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
KPTI next annual earnings announcement has not yet been scheduled

OtherKPTIprofitabilitymetrics:

Annual Revenue

$145.24 M
KPTI annual revenue is $145.24 million

Annual Net Income

-$76.42 M
KPTI annual net profit is -$76.42 million

Annual EBIT

-$38.94 M
KPTI annual earnings before interest & taxes is -$38.94 million

Annual EPS

-$0.93
KPTI annual earnings per share is -$0.93

Quarterly EBITDA

N/A

December 31, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

KPTI Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$46.68 M
KPTI quarterly EBITDA is currently at an all-time high

3-Year Low

-$42.48 M
KPTI quarterly EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
KPTI previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

N/A
KPTI next earnings announcement has not yet been scheduled

OtherKPTIprofitabilitymetrics:

Quarterly Revenue

$30.54 M
KPTI quarterly revenue is $30.54 million

Quarterly Net Income

-$30.78 M
KPTI quarterly net profit is -$30.78 million

Quarterly EBIT

-
KPTI quarterly earnings before interest & taxes value is unknown

Quarterly EPS

-$0.24
KPTI quarterly earnings per share is -$0.24

TTM EBITDA

N/A

December 31, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

KPTI TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$3.60 M
KPTI TTM EBITDA is currently at an all-time high

3-Year Low

-$139.31 M
KPTI TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
KPTI previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

N/A
KPTI next earnings announcement has not yet been scheduled

OtherKPTIprofitabilitymetrics:

TTM Revenue

$145.24 M
KPTI TTM revenue is $145.24 million

TTM Net Income

-$76.42 M
KPTI TTM net profit is -$76.42 million

TTM EBIT

-
KPTI TTM earnings before interest & taxes value is unknown

TTM EPS

-$1.02
KPTI TTM earnings per share is -$1.02

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$38.60 M
KPTI annual EBITDA is -$38.60 million

Annual Net Income

-$76.42 M
KPTI annual net profit is -$76.42 million

Annual Interest Expense

$37.42 M
KPTI annual interest expense is $37.42 million

Annual Income Tax

$57.00 K
KPTI annual income tax is $57.00 thousand

Annual D&A

$340.00 K
KPTI annual depreciation & amortization is $340.00 thousand

KPTI EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+67.4%--
3 y3 years+60.2%--
5 y5 years+78.9%--

KPTI EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+72.3%
5 y5-yearat high+78.9%
alltimeall time-277.4%+78.9%

Karyopharm Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
-$38.60 M(-67.4%)
-
-
Sep 2024
-
-$20.58 M(-162.5%)
-$54.42 M(-12.5%)
Jun 2024
-
$32.90 M(-205.0%)
-$62.19 M(-48.9%)
Mar 2024
-
-$31.32 M(-11.6%)
-$121.72 M(+2.8%)
Dec 2023
-$118.42 M(-15.0%)
-$35.42 M(+25.0%)
-$118.42 M(+2.6%)
Sep 2023
-
-$28.34 M(+6.4%)
-$115.44 M(-1.4%)
Jun 2023
-
-$26.64 M(-5.0%)
-$117.08 M(-11.9%)
Mar 2023
-
-$28.02 M(-13.6%)
-$132.92 M(-4.6%)
Dec 2022
-$139.31 M(+43.6%)
-$32.44 M(+8.2%)
-$139.31 M(+131.4%)
Sep 2022
-
-$29.98 M(-29.4%)
-$60.19 M(-18.3%)
Jun 2022
-
-$42.48 M(+23.5%)
-$73.72 M(-7.2%)
Mar 2022
-
-$34.41 M(-173.7%)
-$79.46 M(-18.1%)
Dec 2021
-$96.98 M(-42.2%)
$46.68 M(-207.3%)
-$96.98 M(-46.0%)
Sep 2021
-
-$43.51 M(-9.8%)
-$179.69 M(-1.6%)
Jun 2021
-
-$48.22 M(-7.2%)
-$182.60 M(+5.1%)
Mar 2021
-
-$51.94 M(+44.1%)
-$173.67 M(+3.5%)
Dec 2020
-$167.85 M(-8.2%)
-$36.03 M(-22.4%)
-$167.85 M(-3.4%)
Sep 2020
-
-$46.41 M(+18.1%)
-$173.76 M(+5.1%)
Jun 2020
-
-$39.29 M(-14.8%)
-$165.35 M(-0.5%)
Mar 2020
-
-$46.11 M(+10.0%)
-$166.13 M(-9.2%)
Dec 2019
-$182.93 M(+4.4%)
-$41.93 M(+10.3%)
-$182.93 M(-6.9%)
Sep 2019
-
-$38.01 M(-5.2%)
-$196.50 M(-4.8%)
Jun 2019
-
-$40.08 M(-36.3%)
-$206.37 M(+3.3%)
Mar 2019
-
-$62.91 M(+13.3%)
-$199.78 M(+14.1%)
Dec 2018
-$175.15 M
-$55.51 M(+15.9%)
-$175.15 M(+11.3%)
DateAnnualQuarterlyTTM
Sep 2018
-
-$47.88 M(+43.0%)
-$157.31 M(+12.1%)
Jun 2018
-
-$33.49 M(-12.5%)
-$140.31 M(+2.9%)
Mar 2018
-
-$38.28 M(+1.6%)
-$136.39 M(+6.4%)
Dec 2017
-$128.21 M(+17.9%)
-$37.66 M(+22.0%)
-$128.21 M(+10.3%)
Sep 2017
-
-$30.88 M(+4.4%)
-$116.24 M(+4.8%)
Jun 2017
-
-$29.57 M(-1.7%)
-$110.92 M(-0.6%)
Mar 2017
-
-$30.10 M(+17.1%)
-$111.65 M(+2.7%)
Dec 2016
-$108.72 M(-8.2%)
-$25.69 M(+0.5%)
-$108.72 M(-3.1%)
Sep 2016
-
-$25.56 M(-15.6%)
-$112.16 M(-4.2%)
Jun 2016
-
-$30.30 M(+11.5%)
-$117.04 M(-2.1%)
Mar 2016
-
-$27.17 M(-6.7%)
-$119.60 M(+1.0%)
Dec 2015
-$118.44 M(+57.0%)
-$29.13 M(-4.3%)
-$118.44 M(+2.9%)
Sep 2015
-
-$30.45 M(-7.3%)
-$115.06 M(+10.4%)
Jun 2015
-
-$32.86 M(+26.3%)
-$104.25 M(+18.7%)
Mar 2015
-
-$26.01 M(+1.1%)
-$87.80 M(+16.4%)
Dec 2014
-$75.45 M(+123.2%)
-$25.74 M(+31.1%)
-$75.45 M(+22.1%)
Sep 2014
-
-$19.64 M(+19.7%)
-$61.82 M(+20.1%)
Jun 2014
-
-$16.41 M(+20.0%)
-$51.47 M(+22.8%)
Mar 2014
-
-$13.67 M(+12.9%)
-$41.90 M(+23.9%)
Dec 2013
-$33.80 M(+114.4%)
-$12.11 M(+30.4%)
-$33.80 M(+30.5%)
Sep 2013
-
-$9.28 M(+35.8%)
-$25.90 M(+28.1%)
Jun 2013
-
-$6.83 M(+22.6%)
-$20.22 M(+51.1%)
Mar 2013
-
-$5.58 M(+32.5%)
-$13.39 M(+71.4%)
Dec 2012
-$15.77 M(+54.1%)
-$4.21 M(+16.9%)
-$7.81 M(+116.9%)
Sep 2012
-
-$3.60 M
-$3.60 M
Dec 2011
-$10.23 M
-
-

FAQ

  • What is Karyopharm Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Karyopharm Therapeutics?
  • What is Karyopharm Therapeutics annual EBITDA year-on-year change?
  • What is the all time high quarterly EBITDA for Karyopharm Therapeutics?
  • What is the all time high TTM EBITDA for Karyopharm Therapeutics?

What is Karyopharm Therapeutics annual EBITDA?

The current annual EBITDA of KPTI is -$38.60 M

What is the all time high annual EBITDA for Karyopharm Therapeutics?

Karyopharm Therapeutics all-time high annual EBITDA is -$10.23 M

What is Karyopharm Therapeutics annual EBITDA year-on-year change?

Over the past year, KPTI annual EBITDA has changed by +$79.82 M (+67.40%)

What is the all time high quarterly EBITDA for Karyopharm Therapeutics?

Karyopharm Therapeutics all-time high quarterly EBITDA is $46.68 M

What is the all time high TTM EBITDA for Karyopharm Therapeutics?

Karyopharm Therapeutics all-time high TTM EBITDA is -$3.60 M